Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kezar Life Sciences to Participate in Two Upcoming Investor Conferences By: Kezar Life Sciences, Inc. via Business Wire November 09, 2022 at 16:01 PM EST Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date/Time: Wednesday, November 16, 2022, at 8:35 AM GMT Presenter: Noreen Roth Henig, M.D., Chief Medical Officer Format: Fireside Chat Event: Evercore ISI 5th Annual HealthCONx Conference Location: Boston, MA Date/Time: Wednesday, November 30, 2022, at 12:10 PM ET Presenters: John Fowler, Co-Founder, Chief Executive Officer Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005819/en/Contacts Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs gjain@kezarbio.com Media Contact: Julia Deutsch Solebury Strategic Communications jdeutsch@soleburystrat.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences By: Kezar Life Sciences, Inc. via Business Wire November 09, 2022 at 16:01 PM EST Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date/Time: Wednesday, November 16, 2022, at 8:35 AM GMT Presenter: Noreen Roth Henig, M.D., Chief Medical Officer Format: Fireside Chat Event: Evercore ISI 5th Annual HealthCONx Conference Location: Boston, MA Date/Time: Wednesday, November 30, 2022, at 12:10 PM ET Presenters: John Fowler, Co-Founder, Chief Executive Officer Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005819/en/Contacts Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs gjain@kezarbio.com Media Contact: Julia Deutsch Solebury Strategic Communications jdeutsch@soleburystrat.com
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date/Time: Wednesday, November 16, 2022, at 8:35 AM GMT Presenter: Noreen Roth Henig, M.D., Chief Medical Officer Format: Fireside Chat Event: Evercore ISI 5th Annual HealthCONx Conference Location: Boston, MA Date/Time: Wednesday, November 30, 2022, at 12:10 PM ET Presenters: John Fowler, Co-Founder, Chief Executive Officer Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005819/en/
Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs gjain@kezarbio.com Media Contact: Julia Deutsch Solebury Strategic Communications jdeutsch@soleburystrat.com
